Agreement between commercially available ELISA and in-house Luminex SARS-CoV-2 antibody immunoassays
View ORCID ProfileRebeca Santano, Diana Barrios, Fàtima Crispi, Francesca Crovetto, Marta Vidal, Jordi Chi, View ORCID ProfileLuis Izquierdo, Eduard Gratacós, Gemma Moncunill, View ORCID ProfileCarlota Dobaño
doi: https://doi.org/10.1101/2021.03.09.21252401
Rebeca Santano
aISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Catalonia, Spain
Diana Barrios
aISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Catalonia, Spain
Fàtima Crispi
bBCNatal, Barcelona Center for Maternal-Fetal and Neonatal Medicine, Hospital Sant Joan de Déu and Hospital Clínic, IDIBAPS, Universitat de Barcelona, CIBER-ER, Barcelona, Spain
Francesca Crovetto
bBCNatal, Barcelona Center for Maternal-Fetal and Neonatal Medicine, Hospital Sant Joan de Déu and Hospital Clínic, IDIBAPS, Universitat de Barcelona, CIBER-ER, Barcelona, Spain
Marta Vidal
aISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Catalonia, Spain
Jordi Chi
aISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Catalonia, Spain
Luis Izquierdo
aISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Catalonia, Spain
Eduard Gratacós
bBCNatal, Barcelona Center for Maternal-Fetal and Neonatal Medicine, Hospital Sant Joan de Déu and Hospital Clínic, IDIBAPS, Universitat de Barcelona, CIBER-ER, Barcelona, Spain
Gemma Moncunill
aISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Catalonia, Spain
Carlota Dobaño
aISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Catalonia, Spain
![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Data Availability
The authors confirm that the data supporting the findings of this study are available within the article. Raw data of this study are available from the corresponding author R.S. on request.
Posted March 10, 2021.
Agreement between commercially available ELISA and in-house Luminex SARS-CoV-2 antibody immunoassays
Rebeca Santano, Diana Barrios, Fàtima Crispi, Francesca Crovetto, Marta Vidal, Jordi Chi, Luis Izquierdo, Eduard Gratacós, Gemma Moncunill, Carlota Dobaño
medRxiv 2021.03.09.21252401; doi: https://doi.org/10.1101/2021.03.09.21252401
Agreement between commercially available ELISA and in-house Luminex SARS-CoV-2 antibody immunoassays
Rebeca Santano, Diana Barrios, Fàtima Crispi, Francesca Crovetto, Marta Vidal, Jordi Chi, Luis Izquierdo, Eduard Gratacós, Gemma Moncunill, Carlota Dobaño
medRxiv 2021.03.09.21252401; doi: https://doi.org/10.1101/2021.03.09.21252401
Subject Area
Subject Areas
- Addiction Medicine (347)
- Allergy and Immunology (666)
- Anesthesia (181)
- Cardiovascular Medicine (2637)
- Dermatology (223)
- Emergency Medicine (398)
- Epidemiology (12211)
- Forensic Medicine (10)
- Gastroenterology (758)
- Genetic and Genomic Medicine (4087)
- Geriatric Medicine (387)
- Health Economics (680)
- Health Informatics (2646)
- Health Policy (1003)
- Hematology (362)
- HIV/AIDS (850)
- Medical Education (399)
- Medical Ethics (109)
- Nephrology (433)
- Neurology (3863)
- Nursing (209)
- Nutrition (577)
- Oncology (2022)
- Ophthalmology (584)
- Orthopedics (240)
- Otolaryngology (304)
- Pain Medicine (250)
- Palliative Medicine (75)
- Pathology (472)
- Pediatrics (1113)
- Primary Care Research (450)
- Public and Global Health (6516)
- Radiology and Imaging (1398)
- Respiratory Medicine (871)
- Rheumatology (404)
- Sports Medicine (342)
- Surgery (444)
- Toxicology (52)
- Transplantation (185)
- Urology (165)